All Oncology News

Jeffrey S. Weber, MD, PhD, expands on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma.

Treatment with JBI-802, the first-in-class CoREST inhibitor with dual LSD1 and HDAC6 activity was shown to be safe and active.

An MAA seeking the approval of lazertinib plus amivantamab in the first-line treatment of adult patients with EGFR+ NSCLC has been submitted to the EMA.

Florida Cancer Specialists & Research Institute physicians were recognized in 2023 by several magazines as top doctors in their local communities.

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

Doctors diagnosed Christopher Gregg, PhD, with stage IV metastatic breast cancer in 2018. Then, he started thinking of ways to improve his treatment.

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome radiation oncologist Bradford Perez, MD to the statewide practice.

Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide, followed by a taxane, concomitant with trastuzumab/pertuzumab elicited responses in patients with HER2+ breast cancer.

The FDA has approved pembrolizumab (Keytruda) plus chemoradiation for patients with FIGO 2014 stage III to IVA cervical cancer.

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

Joshua Hurwitz, MD, shares how multifocal MRI-directed SIB plus SBRT was not linked with added toxicity vs unifocal SIB in patients with prostate cancer.

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies.

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension linked with BTK inhibitors in chronic lymphocytic leukemia.

Neal Shore, MD, FACS, highlights the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

National Family Caregivers Month is observed every November to honor the contributions and sacrifices caregivers make to support their loved ones.

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway by inhibiting the transcription function of TEAD-YAP.function of TEAD-YAP.

Charles Swanton, FRCP, BSc, PhD, has a craving to understand cancer’s evolution, and his list of achievements can prove it.

The FDA has granted fast track designation to SLS009 for use in patients with relapsed or refractory acute myeloid leukemia.

R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma.

The European Commission has granted conditional marketing authorization to adagrasib for patients with KRAS G12C+ advanced non–small cell lung cancer.

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.